Residual Payments. MPL shall pay to Distributor residual payments following the expiration or termination of this Agreement, as follows: for the first twelve (12) month period following the expiration or termination of this Agreement, and payable within forty five (45) days after such expiration or termination, an amount equal to thirty percent (30%) of Average Annual Net Sales; and for the second twelve (12) month period following the expiration or termination of this Agreement, and payable within forty-five (45) days after the first anniversary of such expiration of termination, an amount equal to fifteen percent (15%) Average Annual Net Sales. For purposes of this Agreement, "Average Annual Net Sales" shall be calculated as follows: (A/B) x 12 where, A = total Net Sales from the Effective Date through the date of expiration or termination; and B = the total number of months that have elapsed from the Effective Date through the date of expiration or termination. In no event are the payments set forth above to be considered cumulative payments (i.e., more than forty-five percent (45%) of Average Annual Net Sales). In the event that it is determined that Distributor is in breach of the payment obligations under Section 5.07 of this Agreement, MPL shall be entitled to offset any amounts due and owing MPL against the residual payments due and owing Distributor under this Section 12.07.
Residual Payments. Lender shall be entitled to receive 100% of the Residuals attributable to any Facility Contract until Lender shall have recovered the balloon payment/Estimated Residual amount set forth in the applicable Amortization Schedule (which Lender shall have full recourse to Borrower).
Residual Payments. In the event that both Novartis and Genentech terminate this Agreement as set forth in Section 18.3(c) and Tanox chooses to continue Development and Commercialization of Anti-IgE Products, Tanox shall pay to Novartis and Genentech, ***** in the aggregate:
(i) For the period, if any, beginning as of the effective date of termination and ending on the date that is *****: (A) ***** of Worldwide net sales (calculated in a manner consistent with that set forth in the Financial Appendix) of Anti-IgE Antibodies and Anti-IgE Products sold by Tanox, an Affiliate or sublicensee; plus (B) ***** of Worldwide net profits (calculated in a manner consistent with the calculation of Net Profits (U.S.) minus Sales Costs (U.S.) set forth in the Financial Appendix) of Tanox and/or applicable Affiliates and sublicensees from Anti-IgE Products (where costs incurred by Tanox which are directly related to the transfer to Tanox of the continued Development and Commercialization of Anti-IgE Products shall be deducted in the calculation of such net profits); and
(ii) For the period beginning on the date that is ***** and continuing thereafter: (A) ***** of net sales in any country (calculated in a manner consistent with that set forth in the Financial Appendix) of Anti-IgE Antibodies and Anti-IgE Products sold by Tanox, an Affiliate or sublicensee, the manufacture, use or sale of which would infringe a Valid Claim of an Anti-IgE Patent in such country Controlled by either or both of Genentech or Novartis and licensed to Tanox under Section 18.3(c) and Part 1 of Schedule D (it being understood that no such ***** royalty shall be due in the absence of any such Valid Claim); plus (B) ***** of Worldwide net profits (calculated in a manner consistent with the calculation of Net Profits (U.S.) minus Sales Costs (U.S.) set forth in the Financial Appendix) of Tanox and/or applicable Affiliates and sublicensees from Anti-IgE Products (where costs incurred by Tanox which are directly related to the transfer to Tanox of the continued Development and Commercialization of Anti-IgE Products shall be deducted in the calculation of such net profits). *****
Residual Payments. If Content Provider chooses to promote or market to its Subscribers products and services offered by Point2, Content Provider will receive the Residual Rate described in Exhibit D.
Residual Payments. During the Term, ProPay agrees to pay Client Residual Payments calculated in accordance with schedule A-1 for Direct Sub-merchants and schedule A-2 for Indirect Sub-merchants. Client will not be eligible for Residual Payments relating to the same merchant on more than one schedule and in the event of a dispute, ProPay will reasonably determine the proper classification of a merchant for purposes of this section. It is expressly understood that Client will not be entitled to any Residual Payments with respect to merchants of referral partners or ProFacs referred to ProPay by a Referred Partner. For the avoidance of doubt, if Client has been referred by a referring party, such referring party is named on schedule A-1 to this agreement. If it is discovered that Client was referred by another entity and such is not indicated on schedule A-1, ProPay reserves the right to amend schedule A-1.
Residual Payments. If you transfer holdings to your Platform Account from a third-party investment manager or another platform, and Hubwise subsequently receive a payment from them - such as a distribution or tax reclaim - the payment will be credited to your Cash Account, Cash Reserve or Scheme Bank Account, as appropriate. In specie transfers are not accepted. Any holdings you wish to transfer will need to be sold and the cash transferred onto the platform. You should be aware that any such sales may result in a personal capital gains tax liability where they do not benefit from tax concessions within ISA or SIPP Accounts. Further information about the transfer process is contained in the GIA and ISA Client Agreements contained in these T&Cs below. Hubwise additional Platform information You can opt at any time to start regular monthly contributions into your GIA, ISA, and/or SIPP or to change an existing arrangement for Regular Contributions subject to specific product constraints. Regular Contributions set up online must be paid for by Direct Debit from your Nominated Bank Account and must be for a minimum of £100 per month. When making a Regular Contribution into GIAs and ISAs, Direct Debit instructions must be received 10 working days prior to the next available collection date, and the first Direct Debit collection will be made on or just after the 18th calendar day of that month or the following month if the instruction is not received in time. All future Regular Contributions will be taken on the 18th calendar day of the month or the next working day thereafter. Amendments to Regular Contributions must be received by Investment Champion at least seven Business Days before the 18th calendar day of the month if you wish them to take effect that month. You are responsible for ensuring you do not subscribe to multiple ISAs in any given tax year, as we are unable to validate your application in this regard. If a regular contribution to your ISA exceeds the permitted HM Treasury limit in any tax year, a GIA will be created and the contribution will be added to that Account and invested in the Investment Champion Model Portfolio, as selected for the ISA. Monies to fund Regular Contributions into a SIPP will be taken from the Nominated Bank account linked to your SIPP on the monthly calendar date chosen by you. If you wish to change the amount of your Regular Contributions, please contact Investment Champion. See also ‘Minimum investments’ section on page 14 of these T&Cs. ...
Residual Payments. The "Residual Payments" shall be the payments to be made to the Stockholders from time to time from the Escrow Fund in accordance with Section 9.3 and the Escrow Agreement.
Residual Payments. Subject to the provisions of Section 11.6, in consideration of Cephalon's efforts in developing Product goodwill, Xxxxxx shall pay the following commissions to Cephalon during each Residual Period following the expiration or termination of the Collaboration Period. The commission payments due for the Residual Periods shall be made within forty-five (45) days following the end of each Residual Period: [* The confidential material contained herein has been omitted and has been separately filed with the Commission.] [* The confidential material contained herein has been omitted and has been separately filed with the Commission.]
Residual Payments. All the terms of the applicable ACTRA agreement and clauses shall apply to any engagement day or portion thereof not covered by these Clauses.
Residual Payments. Upon expiration or termination of this Agreement, with the exception of termination by Company pursuant to Section 14.3 of this Agreement, Company shall continue to pay Vendor on a monthly basis, in arrears, for a period of [CONFIDENTIAL TREATMENT REQUESTED] after such expiration or termination, residual payments as follows: the residual payments shall equal [CONFIDENTIAL TREATMENT REQUESTED]; provided, however, such residual payment percentage may be reduced as follows: In the event Company increases the number of Representatives hired by Vendor under this Agreement (as set forth in Section 2.1 of this Agreement), the residual payment shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED]. Further, if this Agreement is extended beyond the initial five (5) year term in accordance with Section 14.1 of this Agreement, the residual payment shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED]. For purposes hereof, the number of Representatives and the related residual fee shall be determined as of the first day of each calendar month. This Section shall not limit any damages to which either Vendor may be entitled as a result of Company's breach. During the term of this Agreement and thereafter as long as residual payments are due to Vendor pursuant to this Section 14.13, Company shall provide to Vendor monthly sales reports in a mutually agreed upon format. Such sales reports shall be provided to Vendor electronically within ten (10) days of the end of each month. During the term of this Agreement and for a period of one (1) year after the final residual payment owed to Company is made by Vendor, Company shall permit Vendor's designated employees or agents to have access during ordinary business hours to records of all Product sales information in order to verify the accuracy of amounts paid to Vendor by Company.
